天士力：前三季度净利润同比增长16.88%至9.84亿元

Core Viewpoint - Tianjin Tasly Pharmaceutical Group Co., Ltd. reported a decline in revenue for Q3 2025, while net profit showed growth, indicating mixed financial performance [1] Financial Performance - In Q3 2025, the company achieved revenue of 2.022 billion yuan, a year-on-year decrease of 3.27% [1] - The net profit attributable to shareholders for Q3 2025 was 210 million yuan, reflecting a year-on-year increase of 16.56% [1] - For the first three quarters of 2025, total revenue reached 6.311 billion yuan, down 2.35% compared to the same period last year [1] - The net profit attributable to shareholders for the first three quarters was 984 million yuan, which is a year-on-year increase of 16.88% [1] Revenue Breakdown - The revenue from the pharmaceutical manufacturing segment decreased by 0.47% year-on-year [1] - The revenue from the pharmaceutical commerce segment saw a significant decline of 16.70% year-on-year [1]